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Abstract Postherpetic neuralgia has been variably
defined but is generally understood to be pain that persists
for longer than a few months after an attack of herpes
zoster. Pain persists for years in approximately 10 % of
those afflicted with acute herpes zoster. The likelihood of
postherpetic neuralgia increases with older age, severity
of the zoster, trigeminal location, and other factors.
Postherpetic neuralgia is a neuropathic pain and treatment
usually involves sequential trials of topical and systemic
drugs; a variety of other therapies may be considered in
refractory cases. A new topical capsaicin 8 % patch has
been approved for this indication based on the positive
studies in patients with non-trigeminal postherpetic neu-
ralgia. Experience with the use of the capsaicin 8 % patch
for trigeminal distribution neuralgia is lacking. We report a
case of trigeminal postherpetic neuralgia which was safely
and effectively treated with capsaicin 8 % patch.
Introduction
Postherpetic neuralgia (PHN) is the persistence of pain
after the disappearance of the rash caused by the herpes
zoster virus [1]. The definition of PHN has been contro-
versial, ranging from pain persisting after the healing of
rash to pain that continues beyond a period that varies
between 1 and 6 months [2]. Risk factors for PHN include
older age, immunosuppression, female gender, presence of
prodrome, greater rash severity, and greater acute pain
[3–5]. The thoracic dermatomes are most commonly
affected, followed by the region innervated by the ophthalmic
division of the trigeminal nerve [6, 7], particularly that
supplied by the frontal branch of V1 [1].
Although PHN may decline over time, chronic pain
continues indefinitely in approximately 10 % of those
afflicted. For many patients, the chronic neuropathic pain
has a profound adverse effect on function and quality of
life. Numerous treatments are considered, including both
topical therapies and systemic treatment with a variety of
drugs. Antidepressants, gabapentin, pregabalin, opioids,
and topical lidocaine have been shown to be efficacious in
randomized controlled studies [8, 9] and many other drug
therapies, interventional approaches, and psychological or
rehabilitative treatments are tried empirically in those with
persistent pain [10–13].
Low concentration topical capsaicin has been used for
decades as a treatment for PHN, with equivocal results
[14]. In recent years, a high concentration (8 %) capsaicin
patch has been developed, and approved for PHN based on
two randomized controlled studies demonstrating the effi-
cacy and safety of a 1-h application for PHN in non-tri-
geminal dermatomal distributions [15, 16]. This treatment
may reduce pain for many months and the controlled trials
suggest that a typical responder will experience improve-
ment for approximately 3 months.
The capsaicin 8 % patch has not been studied for tri-
geminal PHN, and the feasibility, safety and efficacy of the
patch when used on the face and head remains to be
determined. We present a case of PHN in the trigeminal
nerve dermatomal distribution which responded to treat-
ment with capsaicin 8 % topical patch.
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Case
A 64-year-old woman with past medical history of
depression, migraine, gastroesophageal reflux disease,
carpal tunnel syndrome and benign breast mass removal
initially presented to the Department of Pain Medicine and
Palliative Care at Beth Israel Medical Center with right
facial pain following a V1 trigeminal herpes zoster erup-
tion approximately 4 weeks earlier. The acute infection
was complicated by an anterior uveitis and altered mental
status associated with an abnormal MRI, specifically high
T2 signal in bilateral superficial occipital lobes. Although
cerebrospinal fluid was normal, the patient was treated with
high dose IV acyclovir for 10 days for a suspected herpes
zoster encephalitis. She rapidly improved, clinically and
radiographically, and was switched to oral valacyclovir for
a brief additional period.
Pain persisted after the acute infection resolved. Trials
of an opioid, pregabalin, and a combination product con-
taining butalbital, acetaminophen, and caffeine were inef-
fective. At the time of presentation to the pain practice, the
patient complained of continuous severe pain in the right
upper cheek, eye, and forehead, with radiation to the right
temporal region. The pain was described as a constant
burning with intermittent electrical shock-like painful
sensations occurring approximately every 10 min, each
lasting several seconds. The burning pain was rated as an
8/10 on an 11-point verbal numerical pain rating scale. The
affected area was sensitive to touch, heat (e.g., when
washing hair with hot water), and combing hair. The
patient had difficulty with opening her right eye. The pain
greatly interfered with her ability to function and she was
very dysphoric.
On the initial examination, the skin was discolored and
erythematous in the right V1 distribution. The affected area
demonstrated hyperalgesia and allodynia. Otherwise, the
neurological examination was normal.
The patient was diagnosed with trigeminal PHN based
on the history of persistent pain (lasting more than 1 month
since the acute infection resolved). Pregabalin was con-
tinued (highest dose of 150 mg orally three times daily)
and additional drugs were tried, including duloxetine
(highest dose of 60 mg daily), tapentadol (highest dose
200 mg daily), oxymorphone (highest dose 20 mg daily),
and morphine sulfate extended release (highest dose of
60 mg daily). With the exception of morphine, which
provided slight benefit, the latter drugs did not provide
more relief at the maximum tolerated doses. The patient
was also briefly treated with gabapentin but had to dis-
continue the medication due to adverse effects.
Approximately 6 weeks after the zoster eruption, pain
was still severe despite treatment with pregabalin and
morphine. The patient consented to a trial of topical
capsaicin treatment. She received a single 60-min appli-
cation of the topical capsaicin 8 % patch (Qutenza)
applied to the right side of her forehead, sparing the area
around the eye. The total dose of capsaicin in the patch was
179 mg. Safety goggles were worn during the application
to further protect the eyes. The skin to which the patch was
applied was pretreated with 20 g of topical anesthetic
lidocaine/prilocaine 2.5 %/2.5 %. Aside from transient
erythema and tolerable application-related pain, the patient
tolerated the procedure well.
Within a few days, she reported substantial pain relief.
At a 1-month follow-up, she indicated that the pain could
be graded at a score of 4–5/10 and the area of pain was
reduced in size, involving a much smaller area on the
forehead. Allodynia also was improved, with only some
small residual patchy allodynic regions left. The patient
was able to open her right eye more with improved visual
acuity and was able to wash and comb her hair.
Approximately 1 year after the procedure the patient
reported the pain score was 1/10, and her medications
included pregabalin 75 mg orally three times daily, dul-
oxetine 60 mg daily and morphine sulfate extended release
total dose of 30 mg daily. Duloxetine was also used for the
treatment of depression. She complained of persistent itch
and the sensation of a ‘‘piece of sand’’ in the right eye at
1-year follow-up. She continues to be followed by the pain
practice and is undergoing tapering of her analgesics.
Discussion
The topical capsaicin 8 % patch provided prompt and
meaningful relief for this patient with trigeminal PHN.
Systemic treatment with pregabalin and an opioid yielded
insufficient relief until the treatment with topical capsaicin,
after which the patient experienced substantial improve-
ment without initial change in her drug regimen. After a
period of reduced pain, the medications could be tapered
without clinical worsening. The pain relief was satisfactory
and associated with improved functioning.
The long-lasting relief of pain in this case was surpris-
ing, but the potential for this outcome was suggested by a
previous 1-year extension study [17]. The latter study
showed that the cohort of patients given up to four
capsaicin 8 % topical patch applications experienced a
prolonged period of reduced pain. It was found that a
decrease in pain scores from baseline was maintained with
subsequent capsaicin 8 % similar topical patch treatments
regardless of the number of treatments received [17].
There is no published experience with the capsaicin 8 %
patch for trigeminal distribution pain. The feasibility and
safety of the approach depends on the ability to fit the patch
to the contours of the affected area while avoiding contact
588 J Headache Pain (2012) 13:587–589
123
with the eyes. This case suggests that the treatment may be
undertaken, with only transient side effects similar to those
previously reported for non-trigeminal cases [15–17].
Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) is
the principal substance in hot chili peppers and has been in
clinical use as a cream to treat various types of painful
conditions [18, 19]. Capsaicin is a highly selective and
potent agonist for the transient receptor potential vanilloid
1 (TRPV1) receptor, a trans-membrane receptor-ion
channel complex, which is involved in responses to noci-
ceptive stimuli and is gated by noxious heat temperature,
low pH, and endogenous lipids [19, 20]. The exact mech-
anism of action of topical capsaicin in pain relief is not
fully understood. It has long been thought that the pain
effects may be due to the reduction of substance P content
in the skin [21], but the recent studies demonstrate that
topical capsaicin also causes defunctionalization of
upregulated and sensitized TRPV1 receptors on sensory
nerve endings [22–24].
This case suggests that the topical capsaicin 8 % patch
can be used in the treatment of trigeminal PHN. With
efforts to protect the eyes and fully apply the patch to the
affected region, the clinical utility of the patch for PHN in
this distribution should parallel that demonstrated in non-
trigeminal conditions. Further study will be needed to
confirm this.
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